TECX

AvroBio Inc

Exchange: NASDAQSector: HealthcareIndustry: Biotechnology

AVROBIO, Inc. is a leading, Phase 2 gene therapy company focused on the development of its investigational gene therapy, AVR-RD-01, in Fabry disease, as well as additional gene therapy programs in other lysosomal storage disorders including Gaucher disease, cystinosis and Pompe disease. The Company’s plato™ platform includes a proprietary vector system, automated cell manufacturing solution and refined conditioning regimen deploying therapeutic drug monitoring. AVROBIO is headquartered in Cambridge, MA and has offices in Toronto, ON.

Current Price

$28.53

-1.69%

Profile

Valuation (TTM)

Market Cap$543.15M

P/E-7.32

EV—

P/B2.16

Shares Out19.04M

P/Sales—

Revenue$0.00

EV/EBITDA—

AvroBio Inc (TECX) Dividends

Dividend Overview

Dividend Yield

—

Dividend / Share

—

Key Metrics

Market Cap

$543.15M

P/E Ratio

-7.32

Forward P/E

—

EPS

$-4.05

PEG Ratio

0.02

Book Value

$13.20

Dividend Yield

—

Profit Margin

—

ROE

-29.50%

Dividend History

Dividend Safety

TECX Dividend Analysis

AvroBio Inc (TECX) dividend analysis including yield, payout history, and sustainability metrics.

P/E ratio: -7.32. Free cash flow: $-60.22M. This page shows AvroBio Inc's dividend overview, key metrics, historical payout data, and dividend safety assessment to help income-focused investors evaluate the sustainability of dividend payments.

GoodMoat's dividend analyzer evaluates payout ratios, earnings coverage, and free cash flow coverage to determine how well supported AvroBio Inc's dividend payments are. Use this analysis alongside the company's financial statements and quality score to make informed income-investing decisions.